Resolution of liver fibrosis: Basic mechanisms and clinical relevance

Seminars in Liver Disease

Volumn 35, Issue 2, 2015, Pages 119-131

  Ramachandran, Prakash ^a   Iredale, John P ^a   Fallowfield, Jonathan A ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

antifibrotic therapy; matrix degradation; myofibroblast fate; proresolution macrophage

Indexed keywords

APOPTOSIS; ARTICLE; CELL AGING; DENDRITIC CELL; GAMMA DELTA T LYMPHOCYTE; HEPATIC MYOFIBROBLAST; HUMAN; IMMUNOCOMPETENT CELL; LIVER CELL; LIVER FIBROSIS; LIVER REGENERATION; MACROPHAGE; MYOFIBROBLAST; NATURAL KILLER CELL; NEUTROPHIL; NONHUMAN; PRIORITY JOURNAL; REVERTANT; SENESCENCE; T LYMPHOCYTE; ANIMAL; CONVALESCENCE; HEPATIC STELLATE CELL; LIVER CIRRHOSIS; METABOLISM; PATHOLOGY; SIGNAL TRANSDUCTION;

ANIMALS; HEPATIC STELLATE CELLS; HUMANS; LIVER CIRRHOSIS; RECOVERY OF FUNCTION; SIGNAL TRANSDUCTION;

EID: 84929309326     PISSN: 02728087     EISSN: 10988971     Source Type: Journal    
DOI: 10.1055/s-0035-1550057     Document Type: Article

References (147)

1. Iredale J. P., Benyon R. C., Pickering J., et al. Mechanisms of spontaneous resolution of rat liver fibrosis. Hepatic stellate cell apoptosis and reduced hepatic expression of metalloproteinase inhibitors. J Clin Invest: 1998; 102 3 538 549
2. Issa R., Williams E., Trim N., et al. Apoptosis of hepatic stellate cells: involvement in resolution of biliary fibrosis and regulation by soluble growth factors. Gut: 2001; 48 4 548 557
3. Ellis E. L., Mann D. A. Clinical evidence for the regression of liver fibrosis. J Hepatol: 2012; 56 5 1171 1180
4. Kweon Y. O., Goodman Z. D., Dienstag J. L., et al. Decreasing fibrogenesis: an immunohistochemical study of paired liver biopsies following lamivudine therapy for chronic hepatitis B. J Hepatol: 2001; 35 6 749 755
5. Poynard T., McHutchison J., Manns M., et al. Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C. Gastroenterology: 2002; 122 5 1303 1313
6. Farci P., Roskams T., Chessa L., et al. Long-term benefit of interferon alpha therapy of chronic hepatitis D: regression of advanced hepatic fibrosis. Gastroenterology: 2004; 126 7 1740 1749
7. Niederau C., Fischer R., Pürschel A., Stremmel W., Häussinger D., Strohmeyer G. Long-term survival in patients with hereditary hemochromatosis. Gastroenterology: 1996; 110 4 1107 1119
8. Cope-Yokoyama S., Finegold M. J., Sturniolo G. C., et al. Wilson disease: histopathological correlations with treatment on follow-up liver biopsies. World J Gastroenterol: 2010; 16 12 1487 1494
9. Czaja A. J., Carpenter H. A. Decreased fibrosis during corticosteroid therapy of autoimmune hepatitis. J Hepatol: 2004; 40 4 646 652
10. Dixon J. B., Bhathal P. S., Hughes N. R., O'Brien P. E. Nonalcoholic fatty liver disease: Improvement in liver histological analysis with weight loss. Hepatology: 2004; 39 6 1647 1654
11. Muretto P., Angelucci E., Lucarelli G. Reversibility of cirrhosis in patients cured of thalassemia by bone marrow transplantation. Ann Intern Med: 2002; 136 9 667 672
12. Hammel P., Couvelard A., O'Toole D., et al. Regression of liver fibrosis after biliary drainage in patients with chronic pancreatitis and stenosis of the common bile duct. N Engl J Med: 2001; 344 6 418 423
13. Marcellin P., Gane E., Buti M., et al. Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study. Lancet: 2013; 381 9865 468 475
14. Chang T. T., Liaw Y. F., Wu S. S., et al. Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B. Hepatology: 2010; 52 3 886 893
15. Shiffman M. L., Sterling R. K., Contos M., et al. Long term changes in liver histology following treatment of chronic hepatitis C virus. Ann Hepatol: 2014; 13 4 340 349
16. Mallet V., Gilgenkrantz H., Serpaggi J., et al. Brief communication: the relationship of regression of cirrhosis to outcome in chronic hepatitis C. Ann Intern Med: 2008; 149 6 399 403
17. Nagula S., Jain D., Groszmann R. J., Garcia-Tsao G. Histological-hemodynamic correlation in cirrhosis-a histological classification of the severity of cirrhosis. J Hepatol: 2006; 44 1 111 117
18. Sethasine S., Jain D., Groszmann R. J., Garcia-Tsao G. Quantitative histological-hemodynamic correlations in cirrhosis. Hepatology: 2012; 55 4 1146 1153
19. Calvaruso V., Burroughs A. K., Standish R., et al. Computer-assisted image analysis of liver collagen: relationship to Ishak scoring and hepatic venous pressure gradient. Hepatology: 2009; 49 4 1236 1244
20. Poynard T., Moussalli J., Munteanu M., et al. FibroFrance-GHPS group. Slow regression of liver fibrosis presumed by repeated biomarkers after virological cure in patients with chronic hepatitis C. J Hepatol: 2013; 59 4 675 683
21. Puche J. E., Saiman Y., Friedman S. L. Hepatic stellate cells and liver fibrosis. Compr Physiol: 2013; 3 4 1473 1492
22. Reeves H. L., Friedman S. L. Activation of hepatic stellate cells - a key issue in liver fibrosis. Front Biosci: 2002; 7 d808 d826
23. Friedman S. L. Hepatic stellate cells: protean, multifunctional, and enigmatic cells of the liver. Physiol Rev: 2008; 88 1 125 172
24. Puche J. E., Lee Y. A., Jiao J., et al. A novel murine model to deplete hepatic stellate cells uncovers their role in amplifying liver damage in mice. Hepatology: 2013; 57 1 339 350
25. Hernandez-Gea V., Friedman S. L. Pathogenesis of liver fibrosis. Annu Rev Pathol: 2011; 6 425 456
26. Iredale J. P., Murphy G., Hembry R. M., Friedman S. L., Arthur M. J. Human hepatic lipocytes synthesize tissue inhibitor of metalloproteinases-1. Implications for regulation of matrix degradation in liver. J Clin Invest: 1992; 90 1 282 287
27. Iredale J. P. Models of liver fibrosis: exploring the dynamic nature of inflammation and repair in a solid organ. J Clin Invest: 2007; 117 3 539 548
28. Iredale J. P. Tissue inhibitors of metalloproteinases in liver fibrosis. Int J Biochem Cell Biol: 1997; 29 1 43 54
29. Iredale J. Defining therapeutic targets for liver fibrosis: exploiting the biology of inflammation and repair. Pharmacol Res: 2008; 58 2 129 136
30. Arthur M. J., Iredale J. P., Mann D. A. Tissue inhibitors of metalloproteinases: role in liver fibrosis and alcoholic liver disease. Alcohol Clin Exp Res: 1999; 23 5 940 943
31. Benyon R. C., Arthur M. JP. Extracellular matrix degradation and the role of hepatic stellate cells. Semin Liver Dis: 2001; 21 3 373 384
32. Iredale J. P., Thompson A., Henderson N. C. Extracellular matrix degradation in liver fibrosis: Biochemistry and regulation. Biochim Biophys Acta: 2013; 1832 7 876 883
33. Hemmann S., Graf J., Roderfeld M., Roeb E. Expression of MMPs and TIMPs in liver fibrosis - a systematic review with special emphasis on anti-fibrotic strategies. J Hepatol: 2007; 46 5 955 975
34. Issa R., Zhou X., Constandinou C. M., et al. Spontaneous recovery from micronodular cirrhosis: evidence for incomplete resolution associated with matrix cross-linking. Gastroenterology: 2004; 126 7 1795 1808
35. Yoshiji H., Kuriyama S., Yoshii J., et al. Tissue inhibitor of metalloproteinases-1 attenuates spontaneous liver fibrosis resolution in the transgenic mouse. Hepatology: 2002; 36 4 Pt 1 850 860
36. Elsharkawy A. M., Oakley F., Mann D. A. The role and regulation of hepatic stellate cell apoptosis in reversal of liver fibrosis. Apoptosis: 2005; 10 5 927 939
37. Watson M. R., Wallace K., Gieling R. G., et al. NF-kappaB is a critical regulator of the survival of rodent and human hepatic myofibroblasts. J Hepatol: 2008; 48 4 589 597
38. Murphy F. R., Issa R., Zhou X., et al. Inhibition of apoptosis of activated hepatic stellate cells by tissue inhibitor of metalloproteinase-1 is mediated via effects on matrix metalloproteinase inhibition: implications for reversibility of liver fibrosis. J Biol Chem: 2002; 277 13 11069 11076
39. Murphy F., Waung J., Collins J., et al. N-Cadherin cleavage during activated hepatic stellate cell apoptosis is inhibited by tissue inhibitor of metalloproteinase-1. Comp Hepatol: 2004; 3 01 S8
40. Zhou X., Murphy F. R., Gehdu N., Zhang J., Iredale J. P., Benyon R. C. Engagement of alphavbeta3 integrin regulates proliferation and apoptosis of hepatic stellate cells. J Biol Chem: 2004; 279 23 23996 24006
41. Issa R., Zhou X., Trim N., et al. Mutation in collagen-1 that confers resistance to the action of collagenase results in failure of recovery from CCl4-induced liver fibrosis, persistence of activated hepatic stellate cells, and diminished hepatocyte regeneration. FASEB J: 2003; 17 1 47 49
42. Oakley F., Trim N., Constandinou C. M., et al. Hepatocytes express nerve growth factor during liver injury: evidence for paracrine regulation of hepatic stellate cell apoptosis. Am J Pathol: 2003; 163 5 1849 1858
43. Trim N., Morgan S., Evans M., et al. Hepatic stellate cells express the low affinity nerve growth factor receptor p75 and undergo apoptosis in response to nerve growth factor stimulation. Am J Pathol: 2000; 156 4 1235 1243
44. Kendall T. J., Hennedige S., Aucott R. L., et al. p75 Neurotrophin receptor signaling regulates hepatic myofibroblast proliferation and apoptosis in recovery from rodent liver fibrosis. Hepatology: 2009; 49 3 901 910
45. Fischer R., Cariers A., Reinehr R., Häussinger D. Caspase 9-dependent killing of hepatic stellate cells by activated Kupffer cells. Gastroenterology: 2002; 123 3 845 861
46. Krizhanovsky V., Yon M., Dickins R. A., et al. Senescence of activated stellate cells limits liver fibrosis. Cell: 2008; 134 4 657 667
47. Borkham-Kamphorst E., Schaffrath C., Van de Leur E., et al. The anti-fibrotic effects of CCN1/CYR61 in primary portal myofibroblasts are mediated through induction of reactive oxygen species resulting in cellular senescence, apoptosis and attenuated TGF-β signaling. Biochim Biophys Acta: 2014; 1843 5 902 914
48. Kim K. H., Chen C. C., Monzon R. I., Lau L. F. Matricellular protein CCN1 promotes regression of liver fibrosis through induction of cellular senescence in hepatic myofibroblasts. Mol Cell Biol: 2013; 33 10 2078 2090
49. Kong X., Feng D., Wang H., et al. Interleukin-22 induces hepatic stellate cell senescence and restricts liver fibrosis in mice. Hepatology: 2012; 56 3 1150 1159
50. Klein S., Klösel J., Schierwagen R., et al. Atorvastatin inhibits proliferation and apoptosis, but induces senescence in hepatic myofibroblasts and thereby attenuates hepatic fibrosis in rats. Lab Invest: 2012; 92 10 1440 1450
51. Simon T. G., King L. Y., Zheng H., Chung R. T. Statin use is associated with a reduced risk of fibrosis progression in chronic hepatitis C. J Hepatol: 2015; 62 1 18 23
52. Kisseleva T., Cong M., Paik Y., et al. Myofibroblasts revert to an inactive phenotype during regression of liver fibrosis. Proc Natl Acad Sci U S A: 2012; 109 24 9448 9453
53. Troeger J. S., Mederacke I., Gwak G. Y., et al. Deactivation of hepatic stellate cells during liver fibrosis resolution in mice. Gastroenterology: 2012; 143 4 1073 83.e22
54. Duffield J. S., Forbes S. J., Constandinou C. M., et al. Selective depletion of macrophages reveals distinct, opposing roles during liver injury and repair. J Clin Invest: 2005; 115 1 56 65
55. Fallowfield J. A., Mizuno M., Kendall T. J., et al. Scar-associated macrophages are a major source of hepatic matrix metalloproteinase-13 and facilitate the resolution of murine hepatic fibrosis. J Immunol: 2007; 178 8 5288 5295
56. Ramachandran P., Pellicoro A., Vernon M. A., et al. Differential Ly-6C expression identifies the recruited macrophage phenotype, which orchestrates the regression of murine liver fibrosis. Proc Natl Acad Sci U S A: 2012; 109 46 E3186 E3195
57. Ide M., Kuwamura M., Kotani T., Sawamoto O., Yamate J. Effects of gadolinium chloride (GdCl(3)) on the appearance of macrophage populations and fibrogenesis in thioacetamide-induced rat hepatic lesions. J Comp Pathol: 2005; 133 2-3 92 102
58. Sunami Y., Leithäuser F., Gul S., et al. Hepatic activation of IKK/NFκB signaling induces liver fibrosis via macrophage-mediated chronic inflammation. Hepatology: 2012; 56 3 1117 1128
59. Pradere J. P., Kluwe J., De Minicis S., et al. Hepatic macrophages but not dendritic cells contribute to liver fibrosis by promoting the survival of activated hepatic stellate cells in mice. Hepatology: 2013; 58 4 1461 1473
60. Karlmark K. R., Weiskirchen R., Zimmermann H. W., et al. Hepatic recruitment of the inflammatory Gr1+ monocyte subset upon liver injury promotes hepatic fibrosis. Hepatology: 2009; 50 1 261 274
61. Wynn T. A., Barron L. Macrophages: master regulators of inflammation and fibrosis. Semin Liver Dis: 2010; 30 3 245 257
62. Henderson N. C., Mackinnon A. C., Farnworth S. L., et al. Galectin-3 expression and secretion links macrophages to the promotion of renal fibrosis. Am J Pathol: 2008; 172 2 288 298
63. Henderson N. C., Mackinnon A. C., Farnworth S. L., et al. Galectin-3 regulates myofibroblast activation and hepatic fibrosis. Proc Natl Acad Sci U S A: 2006; 103 13 5060 5065
64. Traber P. G., Chou H., Zomer E., et al. Regression of fibrosis and reversal of cirrhosis in rats by galectin inhibitors in thioacetamide-induced liver disease. PLoS ONE: 2013; 8 10 e75361
65. Zimmermann H. W., Seidler S., Nattermann J., et al. Functional contribution of elevated circulating and hepatic non-classical CD14CD16 monocytes to inflammation and human liver fibrosis. PLoS ONE: 2010; 5 6 e11049
66. Liaskou E., Zimmermann H. W., Li K. K., et al. Monocyte subsets in human liver disease show distinct phenotypic and functional characteristics. Hepatology: 2013; 57 1 385 398
67. Preisser L., Miot C., Le Guillou-Guillemette H., et al. IL-34 and macrophage colony-stimulating factor are overexpressed in hepatitis C virus fibrosis and induce profibrotic macrophages that promote collagen synthesis by hepatic stellate cells. Hepatology: 2014; 60 6 1879 1890
68. Yang L., Kwon J., Popov Y., et al. Vascular endothelial growth factor promotes fibrosis resolution and repair in mice. Gastroenterology: 2014; 146 5 1339 50.e1
69. Gibbons M. A., MacKinnon A. C., Ramachandran P., et al. Ly6Chi monocytes direct alternatively activated profibrotic macrophage regulation of lung fibrosis. Am J Respir Crit Care Med: 2011; 184 5 569 581
70. Pellicoro A., Aucott R. L., Ramachandran P., et al. Elastin accumulation is regulated at the level of degradation by macrophage metalloelastase (MMP-12) during experimental liver fibrosis. Hepatology: 2012; 55 6 1965 1975
71. Popov Y., Sverdlov D. Y., Bhaskar K. R., et al. Macrophage-mediated phagocytosis of apoptotic cholangiocytes contributes to reversal of experimental biliary fibrosis. Am J Physiol Gastrointest Liver Physiol: 2010; 298 3 G323 G334
72. Mosser D. M., Edwards J. P. Exploring the full spectrum of macrophage activation. Nat Rev Immunol: 2008; 8 12 958 969
73. Tacke F., Zimmermann H. W. Macrophage heterogeneity in liver injury and fibrosis. J Hepatol: 2014; 60 5 1090 1096
74. Holt M. P., Cheng L., Ju C. Identification and characterization of infiltrating macrophages in acetaminophen-induced liver injury. J Leukoc Biol: 2008; 84 6 1410 1421
75. Zigmond E., Samia-Grinberg S., Pasmanik-Chor M., et al. Infiltrating monocyte-derived macrophages and resident kupffer cells display different ontogeny and functions in acute liver injury. J Immunol: 2014; 193 1 344 353
76. Yona S., Kim K. W., Wolf Y., et al. Fate mapping reveals origins and dynamics of monocytes and tissue macrophages under homeostasis. Immunity: 2013; 38 1 79 91
77. Schulz C., Gomez Perdiguero E., Chorro L., et al. A lineage of myeloid cells independent of Myb and hematopoietic stem cells. Science: 2012; 336 6077 86 90
78. Hashimoto D., Chow A., Noizat C., et al. Tissue-resident macrophages self-maintain locally throughout adult life with minimal contribution from circulating monocytes. Immunity: 2013; 38 4 792 804
79. Seki E., de Minicis S., Inokuchi S., et al. CCR2 promotes hepatic fibrosis in mice. Hepatology: 2009; 50 1 185 197
80. Mitchell C., Couton D., Couty J. P., et al. Dual role of CCR2 in the constitution and the resolution of liver fibrosis in mice. Am J Pathol: 2009; 174 5 1766 1775
81. Lin S. L., Castaño A. P., Nowlin B. T., Lupher M. L. Jr, Duffield J. S. Bone marrow Ly6Chigh monocytes are selectively recruited to injured kidney and differentiate into functionally distinct populations. J Immunol: 2009; 183 10 6733 6743
82. Aoyama T., Inokuchi S., Brenner D. A., Seki E. CX3CL1-CX3CR1 interaction prevents carbon tetrachloride-induced liver inflammation and fibrosis in mice. Hepatology: 2010; 52 4 1390 1400
83. Karlmark K. R., Zimmermann H. W., Roderburg C., et al. The fractalkine receptor CX3CR1 protects against liver fibrosis by controlling differentiation and survival of infiltrating hepatic monocytes. Hepatology: 2010; 52 5 1769 1782
84. Baeck C., Wei X., Bartneck M., et al. Pharmacological inhibition of the chemokine C-C motif chemokine ligand 2 (monocyte chemoattractant protein 1) accelerates liver fibrosis regression by suppressing Ly-6C(+) macrophage infiltration in mice. Hepatology: 2014; 59 3 1060 1072
85. Yoshiji H., Kuriyama S., Yoshii J., et al. Vascular endothelial growth factor and receptor interaction is a prerequisite for murine hepatic fibrogenesis. Gut: 2003; 52 9 1347 1354
86. Rosmorduc O. Antiangiogenic therapies in portal hypertension: a breakthrough in hepatology. Gastroenterol Clin Biol: 2010; 34 8-9 446 449
87. Sahin H., Borkham-Kamphorst E., Kuppe C., et al. Chemokine Cxcl9 attenuates liver fibrosis-associated angiogenesis in mice. Hepatology: 2012; 55 5 1610 1619
88. Iredale J. P., Bataller R. Identifying molecular factors that contribute to resolution of liver fibrosis. Gastroenterology: 2014; 146 5 1160 1164
89. Jiao J., Sastre D., Fiel M. I., et al. Dendritic cell regulation of carbon tetrachloride-induced murine liver fibrosis regression. Hepatology: 2012; 55 1 244 255
90. Hume D. A. Macrophages as APC and the dendritic cell myth. J Immunol: 2008; 181 9 5829 5835
91. Kubes P., Mehal W. Z. Sterile inflammation in the liver. Gastroenterology: 2012; 143 5 1158 1172
92. Pellicoro A., Ramachandran P., Iredale J. P., Fallowfield J. A. Liver fibrosis and repair: immune regulation of wound healing in a solid organ. Nat Rev Immunol: 2014; 14 3 181 194
93. Harty M. W., Muratore C. S., Papa E. F., et al. Neutrophil depletion blocks early collagen degradation in repairing cholestatic rat livers. Am J Pathol: 2010; 176 3 1271 1281
94. Radaeva S., Sun R., Jaruga B., Nguyen V. T., Tian Z., Gao B. Natural killer cells ameliorate liver fibrosis by killing activated stellate cells in NKG2D-dependent and tumor necrosis factor-related apoptosis-inducing ligand-dependent manners. Gastroenterology: 2006; 130 2 435 452
95. Melhem A., Muhanna N., Bishara A., et al. Anti-fibrotic activity of NK cells in experimental liver injury through killing of activated HSC. J Hepatol: 2006; 45 1 60 71
96. Jeong W. I., Park O., Gao B. Abrogation of the antifibrotic effects of natural killer cells/interferon-gamma contributes to alcohol acceleration of liver fibrosis. Gastroenterology: 2008; 134 1 248 258
97. Jeong W. I., Park O., Suh Y. G., et al. Suppression of innate immunity (natural killer cell/interferon-γ) in the advanced stages of liver fibrosis in mice. Hepatology: 2011; 53 4 1342 1351
98. Glässner A., Eisenhardt M., Krämer B., et al. NK cells from HCV-infected patients effectively induce apoptosis of activated primary human hepatic stellate cells in a TRAIL-, FasL- and NKG2D-dependent manner. Lab Invest: 2012; 92 7 967 977
99. Wynn T. A. Cellular and molecular mechanisms of fibrosis. J Pathol: 2008; 214 2 199 210
100. Shi Z., Wakil A. E., Rockey D. C. Strain-specific differences in mouse hepatic wound healing are mediated by divergent T helper cytokine responses. Proc Natl Acad Sci U S A: 1997; 94 20 10663 10668
101. Katz S. C., Ryan K., Ahmed N., et al. Obstructive jaundice expands intrahepatic regulatory T cells, which impair liver T lymphocyte function but modulate liver cholestasis and fibrosis. J Immunol: 2011; 187 3 1150 1156
102. Claassen M. A., de Knegt R. J., Tilanus H. W., Janssen H. L., Boonstra A. Abundant numbers of regulatory T cells localize to the liver of chronic hepatitis C infected patients and limit the extent of fibrosis. J Hepatol: 2010; 52 3 315 321
103. Hammerich L., Bangen J. M., Govaere O., et al. Chemokine receptor CCR6-dependent accumulation of γδ T cells in injured liver restricts hepatic inflammation and fibrosis. Hepatology: 2014; 59 2 630 642
104. Desmet V. J., Roskams T. Cirrhosis reversal: a duel between dogma and myth. J Hepatol: 2004; 40 5 860 867
105. Popov Y., Sverdlov D. Y., Sharma A. K., et al. Tissue transglutaminase does not affect fibrotic matrix stability or regression of liver fibrosis in mice. Gastroenterology: 2011; 140 5 1642 1652
106. Wanless I. R., Nakashima E., Sherman M. Regression of human cirrhosis. Morphologic features and the genesis of incomplete septal cirrhosis. Arch Pathol Lab Med: 2000; 124 11 1599 1607
107. Barry-Hamilton V., Spangler R., Marshall D., et al. Allosteric inhibition of lysyl oxidase-like-2 impedes the development of a pathologic microenvironment. Nat Med: 2010; 16 9 1009 1017
108. Pockros P. J., Jeffers L., Afdhal N., et al. Final results of a double-blind, placebo-controlled trial of the antifibrotic efficacy of interferon-gamma1b in chronic hepatitis C patients with advanced fibrosis or cirrhosis. Hepatology: 2007; 45 3 569 578
109. McHutchison J., Goodman Z., Patel K., et al. Farglitizar Study Investigators. Farglitazar lacks antifibrotic activity in patients with chronic hepatitis C infection. Gastroenterology: 2010; 138 4 1365 1373, 1373.e1-1373.e2
110. Fernández M., Semela D., Bruix J., Colle I., Pinzani M., Bosch J. Angiogenesis in liver disease. J Hepatol: 2009; 50 3 604 620
111. Hall A., Germani G., Isgrò G., Burroughs A. K., Dhillon A. P. Fibrosis distribution in explanted cirrhotic livers. Histopathology: 2012; 60 2 270 277
112. Marshall A., Rushbrook S., Davies S. E., et al. Relation between hepatocyte G1 arrest, impaired hepatic regeneration, and fibrosis in chronic hepatitis C virus infection. Gastroenterology: 2005; 128 1 33 42
113. Lorenzini S., Bird T. G., Boulter L., et al. Characterisation of a stereotypical cellular and extracellular adult liver progenitor cell niche in rodents and diseased human liver. Gut: 2010; 59 5 645 654
114. Kallis Y. N., Robson A. J., Fallowfield J. A., et al. Remodelling of extracellular matrix is a requirement for the hepatic progenitor cell response. Gut: 2011; 60 4 525 533
115. Boulter L., Govaere O., Bird T. G., et al. Macrophage-derived Wnt opposes Notch signaling to specify hepatic progenitor cell fate in chronic liver disease. Nat Med: 2012; 18 4 572 579
116. Bird T. G., Lu W. Y., Boulter L., et al. Bone marrow injection stimulates hepatic ductular reactions in the absence of injury via macrophage-mediated TWEAK signaling. Proc Natl Acad Sci U S A: 2013; 110 16 6542 6547
117. Kundu A. K., Nagaoka M., Chowdhury E. H., Hirose S., Sasagawa T., Akaike T. IGF-1 induces growth, survival and morphological change of primary hepatocytes on a galactose-bared polymer through both MAPK and beta-catenin pathways. Cell Struct Funct: 2003; 28 4 255 263
118. Desbois-Mouthon C., Wendum D., Cadoret A., et al. Hepatocyte proliferation during liver regeneration is impaired in mice with liver-specific IGF-1R knockout. FASEB J: 2006; 20 6 773 775
119. Ebrahimkhani M. R., Oakley F., Murphy L. B., et al. Stimulating healthy tissue regeneration by targeting the 5-HT2B receptor in chronic liver disease. Nat Med: 2011; 17 12 1668 1673
120. Kim J. K., Ma D. W., Lee K. S., Paik Y. H. Assessment of hepatic fibrosis regression by transient elastography in patients with chronic hepatitis B treated with oral antiviral agents. J Korean Med Sci: 2014; 29 4 570 575
121. Leeming D. J., Byrjalsen I., Jiménez W., Christiansen C., Karsdal M. A. Protein fingerprinting of the extracellular matrix remodelling in a rat model of liver fibrosis--a serological evaluation. Liver Int: 2013; 33 3 439 447
122. Leeming D. J., Karsdal M. A., Byrjalsen I., et al. Novel serological neo-epitope markers of extracellular matrix proteins for the detection of portal hypertension. Aliment Pharmacol Ther: 2013; 38 9 1086 1096
123. Fuchs B. C., Wang H., Yang Y., et al. Molecular MRI of collagen to diagnose and stage liver fibrosis. J Hepatol: 2013; 59 5 992 998
124. Chow A. M., Tan M., Gao D. S., et al. Molecular MRI of liver fibrosis by a peptide-targeted contrast agent in an experimental mouse model. Invest Radiol: 2013; 48 1 46 54
125. Popov Y., Patsenker E., Stickel F., et al. Integrin alphavbeta6 is a marker of the progression of biliary and portal liver fibrosis and a novel target for antifibrotic therapies. J Hepatol: 2008; 48 3 453 464
126. Ruddell R. G., Oakley F., Hussain Z., et al. A role for serotonin (5-HT) in hepatic stellate cell function and liver fibrosis. Am J Pathol: 2006; 169 3 861 876
127. Forbes S. J., Newsome P. N. New horizons for stem cell therapy in liver disease. J Hepatol: 2012; 56 2 496 499
128. Thomas J. A., Pope C., Wojtacha D., et al. Macrophage therapy for murine liver fibrosis recruits host effector cells improving fibrosis, regeneration, and function. Hepatology: 2011; 53 6 2003 2015
129. Ratziu V., Bedossa P., Francque S. M., et al. Lack of efficacy of an inhibitor of PDE4 in phase 1 and 2 trials of patients with nonalcoholic steatohepatitis. Clin Gastroenterol Hepatol: 2014; 12 10 1724 30.e5
130. Habens F., Srinivasan N., Oakley F., Mann D. A., Ganesan A., Packham G. Novel sulfasalazine analogues with enhanced NF-kB inhibitory and apoptosis promoting activity. Apoptosis: 2005; 10 3 481 491
131. Teixeira-Clerc F., Julien B., Grenard P., et al. CB1 cannabinoid receptor antagonism: a new strategy for the treatment of liver fibrosis. Nat Med: 2006; 12 6 671 676
132. Cong M., Liu T., Wang P., et al. Antifibrotic effects of a recombinant adeno-associated virus carrying small interfering RNA targeting TIMP-1 in rat liver fibrosis. Am J Pathol: 2013; 182 5 1607 1616
133. Parsons C. J., Bradford B. U., Pan C. Q., et al. Antifibrotic effects of a tissue inhibitor of metalloproteinase-1 antibody on established liver fibrosis in rats. Hepatology: 2004; 40 5 1106 1115
134. Roderfeld M., Weiskirchen R., Wagner S., et al. Inhibition of hepatic fibrogenesis by matrix metalloproteinase-9 mutants in mice. FASEB J: 2006; 20 3 444 454
135. Roeb E., Behrmann I., Grötzinger J., Breuer B., Matern S. An MMP-9 mutant without gelatinolytic activity as a novel TIMP-1-antagonist. FASEB J: 2000; 14 12 1671 1673
136. Arabpour M., Poelstra K., Helfrich W., Bremer E., Haisma H. J. Targeted elimination of activated hepatic stellate cells by an anti-epidermal growth factor-receptor single chain fragment variable antibody-tumor necrosis factor-related apoptosis-inducing ligand (scFv425-sTRAIL). J Gene Med: 2014; 16 9-10 281 290
137. Sato Y., Murase K., Kato J., et al. Resolution of liver cirrhosis using vitamin A-coupled liposomes to deliver siRNA against a collagen-specific chaperone. Nat Biotechnol: 2008; 26 4 431 442
138. Douglass A., Wallace K., Parr R., et al. Antibody-targeted myofibroblast apoptosis reduces fibrosis during sustained liver injury. J Hepatol: 2008; 49 1 88 98
139. Yang M. D., Chiang Y. M., Higashiyama R., et al. Rosmarinic acid and baicalin epigenetically derepress peroxisomal proliferator-activated receptor γ in hepatic stellate cells for their antifibrotic effect. Hepatology: 2012; 55 4 1271 1281
140. Zhang S., Wang J., Liu Q., Harnish D. C. Farnesoid X receptor agonist WAY-362450 attenuates liver inflammation and fibrosis in murine model of non-alcoholic steatohepatitis. J Hepatol: 2009; 51 2 380 388
141. Fiorucci S., Rizzo G., Antonelli E., et al. A farnesoid x receptor-small heterodimer partner regulatory cascade modulates tissue metalloproteinase inhibitor-1 and matrix metalloprotease expression in hepatic stellate cells and promotes resolution of liver fibrosis. J Pharmacol Exp Ther: 2005; 314 2 584 595
142. Kim E. J., Cho H. J., Park D., et al. Antifibrotic effect of MMP13-encoding plasmid DNA delivered using polyethylenimine shielded with hyaluronic acid. Mol Ther: 2011; 19 2 355 361
143. Siller-López F., Sandoval A., Salgado S., et al. Treatment with human metalloproteinase-8 gene delivery ameliorates experimental rat liver cirrhosis. Gastroenterology: 2004; 126 4 1122 1133, discussion 949
144. Popov Y., Patsenker E., Bauer M., Niedobitek E., Schulze-Krebs A., Schuppan D. Halofuginone induces matrix metalloproteinases in rat hepatic stellate cells via activation of p38 and NFkappaB. J Biol Chem: 2006; 281 22 15090 15098
145. Fürst G., Schulte am Esch J., Poll L. W., et al. Portal vein embolization and autologous CD133+ bone marrow stem cells for liver regeneration: initial experience. Radiology: 2007; 243 1 171 179
146. Wang J., Zhou X., Cui L., et al. The significance of CD14+ monocytes in peripheral blood stem cells for the treatment of rat liver cirrhosis. Cytotherapy: 2010; 12 8 1022 1034
147. Wasmuth H. E., Lammert F., Zaldivar M. M., et al. Antifibrotic effects of CXCL9 and its receptor CXCR3 in livers of mice and humans. Gastroenterology: 2009; 137 1 309 319, 319.e1-319.e3